Login to Your Account

Motif planning Q1 filing for iclaprim on back of second positive phase III

By Nuala Moran
Staff Writer

Wednesday, October 4, 2017

LONDON – Motif Bio plc reported positive results from the second phase III trial of iclaprim, in which the antibiotic again demonstrated noninferiority to vancomycin, and said it will file a new drug application to the FDA in the first quarter of 2018.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription